Skip to content
HowShorted

Intra-Cellular Therapies Inc. short interest in 2023

In 2023, Intra-Cellular Therapies Inc.'s disclosed short interest ran from 2.73% of shares outstanding on 13 Jan 2023 to 3.96% on 29 Dec 2023, a change of +1.23 percentage points. The year's high was 4.09% on 30 Nov 2023 and its low 2.12% on 31 Jul 2023, averaging 3.10% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.52 days on 30 Nov 2023. Full history: Intra-Cellular Therapies Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Intra-Cellular Therapies Inc. in 2023

2023 in figures

Start of year
2.73% (13 Jan 2023)
End of year
3.96% (29 Dec 2023)
Change
+1.23 pp
High
4.09% (30 Nov 2023)
Low
2.12% (31 Jul 2023)
Average
3.10%
Highest days to cover
5.52 (30 Nov 2023)
SEC filings marked
8

Every report in 2023

Intra-Cellular Therapies Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20232.73%3.80
31 Jan 20232.78%4.93
15 Feb 20232.53%3.72
28 Feb 20233.49%3.47
15 Mar 20232.76%3.2410-K filed, results (8-K)
31 Mar 20233.52%3.31
14 Apr 20233.41%3.54
28 Apr 20233.08%3.60
15 May 20233.71%3.9810-Q filed, results (8-K)
31 May 20233.59%5.39
15 Jun 20233.49%5.05
30 Jun 20232.71%3.74
14 Jul 20232.54%3.68
31 Jul 20232.12%3.40
15 Aug 20232.64%4.0610-Q filed, results (8-K)
31 Aug 20232.66%4.07
15 Sep 20232.32%3.58
29 Sep 20232.93%4.50
13 Oct 20232.78%2.70
31 Oct 20233.28%3.05
15 Nov 20233.55%3.4310-Q filed, results (8-K)
30 Nov 20234.09%5.52
15 Dec 20233.74%3.46
29 Dec 20233.96%4.80

See also: Intra-Cellular Therapies Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.